

In the Claims:

1-24. Canceled.

25. (currently amended) A method for the treatment of a patient having need to inhibit TGF α -HII comprising: administering to the patient a therapeutically effective amount of an antibody that inhibits TGF α -HII and is capable of binding to a polypeptide comprising a member selected from the group consisting of:

- (a) amino acids 1 to 374 of SEQ ID NO:2;
- (b) amino acids 46 to 374 of SEQ ID NO:2;
- (c) amino acids 1 to 309 of SEQ ID NO:2;
- (d) amino acids 46 to 309 of SEQ ID NO:2;
- (e) amino acids 260 to 309 of SEQ ID NO:2;
- (f) a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97160;
- (g) at least 30 contiguous amino acids of SEQ ID NO:2;
- (h) at least 50 contiguous amino acids of SEQ ID NO:2;
- ~~(i) — a polypeptide which is at least 70% identical to the polypeptide of (a), (b) (c), (d), (e), or (f); and~~
- ~~(j)~~(i) a polypeptide fragment of the polypeptide of (a), (b) (c), (d), (e), or (f).

26-30. Canceled

31. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising amino acids 1 to 374 of SEQ ID NO:2.

32. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising amino acids 46 to 374 of SEQ ID NO:2.

33. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising amino acids 1 to 309 of SEQ ID NO:2.

34. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising amino acids 46 to 309 of SEQ ID NO:2.

35. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising amino acids 260 to 309 of SEQ ID NO:2.

36. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97160.

37. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising at least 30 contiguous amino acids of SEQ ID NO:2.

38. (previously presented) The method of claim 25 wherein said antibody is capable of binding to a polypeptide comprising at least 50 contiguous amino acids of SEQ ID NO:2.

39. (previously presented) The method of claim 25 wherein said antibody is polyclonal.

40. (previously presented) The method of claim 25 wherein said antibody is monoclonal.

41. (previously presented) The method of claim 25 wherein said antibody is chimeric.

42. (previously presented) The method of claim 25 wherein said antibody is humanized.

43. (previously presented) The method of claim 25 wherein said antibody is a single-chain antibody.

44. (previously presented) The method of claim 25 wherein said antibody is an Fab fragment.